The pharmaceutical company, Cortexyme, Inc. has outlined a trial of potential Alzheimer’s drug that targets toxic substances released by P. gingivalis, a bacteria linked to gum disease. In a poster presented at the Alzheimer’s Association International Conference today (Wednesday, July 17), researchers provided an overview of the development of the , known as COR388, and how they are working to test its ability to slow the progression of Alzheimer’s symptoms.

More here